Invesaro

Stocks Comparison

ELI LILLY vs Pfizer: revenue, profit, margins and growth compared

ELI LILLY brought in $65.2B of revenue in fiscal 2025, Pfizer $62.6B in fiscal 2025. Revenue changed by +44.7% at ELI LILLY and -1.6% at Pfizer on the year before, so ELI LILLY grew faster. ELI LILLY kept 31.7% of its revenue as net profit, Pfizer 12.4%.

Side by side, latest fiscal year

LLYPFE
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$65.2B$62.6B
Revenue growth+44.7%-1.6%
Net income$20.6B$7.8B
Net margin31.7%12.4%
Free cash flown/a$9.1B
Free cash flow marginn/a14.5%
Earnings per share (diluted)$22.95$1.36
Cash$7.3B$1.1B
Debt$40.9B$64.6B
Price to earnings51.621.1
Market value$1.11T$163.4B
Dividend yield0.53%6.00%
Rank by revenue in sector#11 of 523 · Health care#13 of 523 · Health care

Over the years

Revenue
LLY FY2018: $21.5BLLY FY2019: $22.3BLLY FY2020: $24.5BLLY FY2021: $28.3BLLY FY2022: $28.5BLLY FY2023: $34.1BLLY FY2024: $45BLLY FY2025: $65.2BPFE FY2018: $40.8BPFE FY2019: $40.9BPFE FY2020: $41.7BPFE FY2021: $81.3BPFE FY2022: $101.2BPFE FY2023: $59.6BPFE FY2024: $63.6BPFE FY2025: $62.6BFY18FY19FY20FY21FY22FY23FY24FY25
LLY $65.2BPFE $62.6B
Net income
LLY FY2018: $3.2BLLY FY2019: $8.3BLLY FY2020: $6.2BLLY FY2021: $5.6BLLY FY2022: $6.2BLLY FY2023: $5.2BLLY FY2024: $10.6BLLY FY2025: $20.6BPFE FY2018: $11.2BPFE FY2019: $16BPFE FY2020: $9.2BPFE FY2021: $22BPFE FY2022: $31.4BPFE FY2023: $2.1BPFE FY2024: $8BPFE FY2025: $7.8BFY18FY19FY20FY21FY22FY23FY24FY25
LLY $20.6BPFE $7.8B
Net margin
LLY FY2018: 15.0%LLY FY2019: 37.3%LLY FY2020: 25.2%LLY FY2021: 19.7%LLY FY2022: 21.9%LLY FY2023: 15.4%LLY FY2024: 23.5%LLY FY2025: 31.7%PFE FY2018: 27.3%PFE FY2019: 39.2%PFE FY2020: 22.0%PFE FY2021: 27.0%PFE FY2022: 31.0%PFE FY2023: 3.6%PFE FY2024: 12.6%PFE FY2025: 12.4%FY18FY19FY20FY21FY22FY23FY24FY25
LLY 31.7%PFE 12.4%
Revenue growth
LLY FY2019: +3.8%LLY FY2020: +9.9%LLY FY2021: +15.4%LLY FY2022: +0.8%LLY FY2023: +19.6%LLY FY2024: +32.0%LLY FY2025: +44.7%PFE FY2019: +0.2%PFE FY2020: +1.8%PFE FY2021: +95.2%PFE FY2022: +24.5%PFE FY2023: -41.1%PFE FY2024: +6.8%PFE FY2025: -1.6%FY19FY20FY21FY22FY23FY24FY25
LLY +44.7%PFE -1.6%
Free cash flow
PFE FY2018: $13.8BPFE FY2019: $10.5BPFE FY2020: $12.2BPFE FY2021: $29.9BPFE FY2022: $26BPFE FY2023: $4.8BPFE FY2024: $9.8BPFE FY2025: $9.1BFY18FY19FY20FY21FY22FY23FY24FY25
LLYPFE $9.1B

Fiscal years as each company reports them; the two may end in different months.

Questions about ELI LILLY and Pfizer

Which is bigger by revenue, ELI LILLY or Pfizer?

ELI LILLY is bigger by revenue: $65.2B in fiscal 2025, against $62.6B for Pfizer in fiscal 2025.

Which keeps more of its revenue as profit, ELI LILLY or Pfizer?

ELI LILLY had a net margin of 31.7% in fiscal 2025; Pfizer had 12.4% in fiscal 2025.

Which grew revenue faster, ELI LILLY or Pfizer?

In their latest fiscal years revenue changed by +44.7% at ELI LILLY and -1.6% at Pfizer.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies